Stockscreener 앱 받기
4.54
1.73%
-0.08
전일 마감가:
$4.62
열려 있는:
$4.72
하루 거래량:
506.69K
Relative Volume:
2.20
시가총액:
$32.73M
수익:
$100.44M
순이익/손실:
$-133.16M
주가수익비율:
-0.1762
EPS:
-25.76
순현금흐름:
$-94.85M
1주 성능:
-66.79%
1개월 성능:
-74.18%
6개월 성능:
-51.08%
1년 성능:
-42.02%
1일 변동 폭
$4.52
$5.0028
1주일 범위
$4.2518
$6.51
52주 변동 폭
$4.2518
$19.14
아타라 Stock (ATRA) Company Profile
명칭
Atara Biotherapeutics Inc
전화
805-623-4211
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
ATRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.54 | 33.31M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
아타라 Stock (ATRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-20 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-07-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-05-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 개시 | Evercore ISI | Outperform |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-09-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-06-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-05-23 | 개시 | Stifel | Buy |
| 2019-01-23 | 개시 | Mizuho | Buy |
| 2018-04-10 | 개시 | JP Morgan | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2018-03-05 | 재확인 | Jefferies | Buy |
| 2018-02-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-01-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
아타라 주식(ATRA)의 최신 뉴스
Analyst Calls: Can Ligand Pharmaceuticals Incorporated beat the S P 5002025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
Aug Summary: Will HAFN benefit from green energy policiesStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
(ATRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Atara Bio director Huang James sells $489k in shares By Investing.com - Investing.com South Africa
Atara Bio director Huang James sells $489k in shares - Investing.com
Aug Selloffs: Is Atara Biotherapeutics Inc being accumulated by smart moneyTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel - FinancialContent
Entry Recap: Is Atara Biotherapeutics Inc stock dividend yield sustainableJuly 2025 Retail & Daily Profit Maximizing Tips - Bộ Nội Vụ
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hol - GuruFocus
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Atara receives FDA complete response letter for Ebvallo BLA application - Pharmaceutical Business review -
FDA rejects Atara’s tabelecleucel application in surprise reversal By Investing.com - Investing.com Nigeria
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA - RTTNews
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain - TipRanks
FDA rejects Atara’s tabelecleucel application in surprise reversal - Investing.com
Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus
Atara plummets on FDA Complete Response Letter for tabelecleucel - Seeking Alpha
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Asianet Newsable
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL - CGTLive®
Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub - Fierce Pharma
Why Is Atara Biotherapeutics Stock Sinking Monday?Atara Biotherapeutics (NASDAQ:ATRA) - Benzinga
US FDA declines to approve Atara's therapy for rare blood cancer - Reuters
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next - TechStock²
FDA Rejects Atara's (ATRA) Ebvallo BLA: Calls for New Evidence o - GuruFocus
US FDA declines to approve Atara’s therapy for rare blood cancer - PharmaLive
Atara's cell therapy is again rejected by FDA, cites agency reversing position on single-arm study - Endpoints News
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form - TipRanks
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy By Investing.com - Investing.com UK
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy - Investing.com
FDA says no to rare transplant cancer treatment patients awaited - Stock Titan
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Business Wire
Atara revises tab-cel commercialization milestones with Pierre Fabre - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Shares Down 21.6%What's Next? - MarketBeat
Why Atara Biotherapeutics Inc. stock could be next big winnerJuly 2025 Sentiment & Weekly High Conviction Ideas - Улправда
Why Atara Biotherapeutics Inc. stock is a value investor pickWeekly Trading Summary & Low Risk High Win Rate Picks - Улправда
Is Atara Biotherapeutics Inc. stock safe for conservative investorsProfit Target & Low Risk High Reward Ideas - Улправда
Why Atara Biotherapeutics Inc. stock attracts global investorsEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics prices $16M public offering - MSN
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears - TipRanks
How Atara Biotherapeutics Inc. stock performs in interest rate cyclesMarket Volume Summary & Fast Moving Stock Trade Plans - Улправда
FDA Decisions to Look For in 1H 2026 - CGTLive®
สล็อตเว็บตรง www.offroadpakistan.com - Early Times
(ATRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Atara Biotherapeutics IncEntered fourth amendment with Pierre FabreSEC filing - marketscreener.com
Weekly Analysts’ Ratings Changes for Atara Biotherapeutics (ATRA) - Defense World
How Atara Biotherapeutics Inc. stock performs in stagflationHead and Shoulders Patterns & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Atara Bio director Huang James sells $489k in shares _newTouch_By Investing.com - Investing.com Nigeria
아타라 (ATRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):